Circulating autoantibodies to LGALS3BP: A novel biomarker for cancer

Disease Markers

Volumn 35, Issue 6, 2013, Pages 747-752

  Grassadonia, Antonino ^a   Tinari, Nicola ^a,b   Natoli, Clara ^a   Yahalom, Galit ^c   Iacobelli, Stefano ^a,b  

^a Department of Experimental and Clinical Sciences G DAnnunzio University   (Italy)

^b MediaPharma Srl   (Italy)

^c Eventus Diagnostics Inc   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIBODY LGALS3BP; IMMUNOGLOBULIN G ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM CANCER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MIDDLE AGED; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT CANCER; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CARRIER PROTEINS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84896906975     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/214595     Document Type: Article

References (45)

1. R. Siegel, D. Naishadham, and A. Jemal, and "Cancer statistics, 2013, and " CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
2. F. A. Coumans, S. Siesling, and L. W. Terstappen, and "Detection of cancer before distant metastasis, and " BMC Cancer, vol. 13, no. 1, article 283, 2013.
3. W. S. Atkin, R. Edwards, I. Kralj-Hans et al. , and "Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial, and " The Lancet, vol. 375, no. 9726, pp. 1624-1633, 2010.
4. B. Levin, D. A. Lieberman, B. McFarland et al. , and "Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a Joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology, and " Gastroenterology, vol. 134, no. 5, pp. 1570-1595, 2008.
5. R. A. Smith, V. Cokkinides, and O. W. Brawley, and "Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening, and " CA Cancer Journal for Clinicians, vol. 62, no. 2, pp. 129-142, 2012.
6. M. G. Wahrenbrock and A. Varki, and "Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the and "tip of the iceberg"?" Cancer Research, vol. 66, no. 4, pp. 2433-2441, 2006.
7. H. H. Wandall, O. Blixt, M. A. Tarp et al. , and "Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes, and " Cancer Research, vol. 70, no. 4, pp. 1306-1313, 2010.
8. M. J. Duffy, D. Evoy, and E. W. McDermott, and "CA 15-3: uses and limitation as a biomarker for breast cancer, and " Clinica Chimica Acta, vol. 411, no. 23-24, pp. 1869-1874, 2010.
9. K. S. Anderson and J. LaBaer, and "The sentinel within: exploiting the immune systemfor cancer biomarkers, and " Journal of Proteome Research, vol. 4, no. 4, pp. 1123-1133, 2005.
10. O. J. Finn, and "Immune response as a biomarker for cancer detection and a lot more, and "The New England Journal ofMedicine, vol. 353, no. 12, Article ID 058157, pp. 1288-1290, 2005.
11. E. M. Tan, and "Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis, and " Journal of Clinical Investigation, vol. 108, no. 10, pp. 1411-1415, 2001.
12. K. S. Anderson, N. Ramachandran, J. Wong et al. , and "Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer, and " Journal of Proteome Research, vol. 7, no. 4, pp. 1490-1499, 2008.
13. P. J. Mintz, J. Kim, K. -A. Do et al. , and "Fingerprinting the circulating repertoire of antibodies from cancer patients, and " Nature Biotechnology, vol. 21, no. 1, pp. 57-63, 2003.
14. S. R. Pereira-Faca, R. Kuick, E. Puravs et al. , and "Identification of 14-3-3 as an antigen that induces a humoral response in lung cancer, and " Cancer Research, vol. 67, no. 24, pp. 12000-12006, 2007.
15. N. Ramachandran, J. V. Raphael, E. Hainsworth et al. , and "Nextgeneration high-density self-assembling functional protein arrays, and " Nature Methods, vol. 5, no. 6, pp. 535-538, 2008.
16. A. Grassadonia, N. Tinari, I. Iurisci et al. , and "90K (Mac-2 BP) and galectins in tumor progression and metastasis, and " Glycoconjugate Journal, vol. 19, no. 7-9, pp. 551-556, 2002.
17. S. Iacobelli, E. Arno, P. Sismondi et al. , and "Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients, and " Breast Cancer Research and Treatment, vol. 11, no. 1, pp. 19-30, 1988.
18. S. Iacobelli, P. Sismondi, M. Giai et al. , and "Prognostic value of a novel circulating serum 90K antigen in breast cancer, and " British Journal of Cancer, vol. 69, no. 1, pp. 172-176, 1994.
19. A. G. Zeimet, C. Natoli, M. Herold et al. , and "Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer, and "The International Journal of Cancer , vol. 68, no. 1, pp. 34-38, 1996.
20. A. Marchetti, N. Tinari, F. Buttitta et al. , and "Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients, and " Cancer Research, vol. 62, no. 9, pp. 2535-2539, 2002.
21. N. Tinari, R. Lattanzio, P. Querzoli et al. , and "High expression of 90K (Mac-2 BP) is associated with poor survival in nodenegative breast cancer patients not receiving adjuvant systemic therapies, and " International Journal of Cancer, vol. 124, no. 2, pp. 333-338, 2009.
22. H. Inohara, S. Akahani, K. Koths, and A. Raz, and "Interactions between galectin-3 and Mac-2-binding protein mediate cellcell adhesion, and " Cancer Research, vol. 56, no. 19, pp. 4530-4534, 1996.
23. T. Sasaki, C. Brakebusch, J. Engel, and R. Timpl, and "Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds1 integrins, collagens and fibronectin, and " The EMBO Journal, vol. 17, no. 6, pp. 1606-1613, 1998.
24. T. A. Ulmer, V. Keeler, L. Loh et al. , and "Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer, and " Journal of Cellular Biochemistry, vol. 98, no. 5, pp. 1351-1366, 2006.
25. Y. -T. Chen, M. J. Scanlan, U. Sahin et al. , and "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, and " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 5, pp. 1914- 1918, 1997.
26. T. Soussi, and "p53 Antibodies in the sera of patients with various types of cancer: a review, and " Cancer Research, vol. 60, no. 7, pp. 1777-1788, 2000.
27. U. Schubert, L. C. Antón, J. Gibbs, C. C. Norbury, J. W. Yewdell, and J. R. Bennink, and "Rapid degradation of a large fraction of newly synthesized proteins by proteasomes, and " Nature, vol. 404, no. 6779, pp. 770-774, 2000.
28. P. Blume-Jensen and T. Hunter, and "Oncogenic kinase signalling, and " Nature, vol. 411, no. 6835, pp. 355-365, 2001.
29. S. Hakomori, and "Tumor-associated carbohydrate antigens, and " Annual Review of Immunology, vol. 2, Article ID 040184, pp. 103-126, 1984.
30. S. -I. Hakomori, and "Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anticancer vaccines, and " Advances in Experimental Medicine and Biology, vol. 491, pp. 369-402, 2001.
31. K. O. Lloyd, and "Philip Levine award lecture. Blood group antigens as markers for normal differentiation and malignant change in human tissues, and " American Journal of Clinical Pathology, vol. 87, no. 1, pp. 129-139, 1987.
32. M. Caron, G. Choquet-Kastylevsky, and R. Joubert-Caron, and "Cancer immunomics using autoantibody signatures for biomarker discovery, and " Molecular and Cellular Proteomics, vol. 6, no. 7, pp. 1115-1122, 2007.
33. F. M. Brichory, D. E. Misek, A. -M. Yim et al. , and "An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer, and " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 17, pp. 9824-9829, 2001.
34. F. Le Naour, D. E. Misek, M. C. Krause et al. , and "Proteomics- based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer, and " Clinical Cancer Research, vol. 7, no. 11, pp. 3328- 3335, 2001.
35. M. J. Nam, J. Madoz-Gurpide, H. Wang et al. , and "Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin Cterminal hydrolase L3, and " Proteomics, vol. 3, no. 11, pp. 2108-2115, 2003.
36. Y. Hirohashi, T. Torigoe, S. Inoda et al. , and "The functioning antigens: beyond just as the immunological targets, and " Cancer Science, vol. 100, no. 5, pp. 798-806, 2009.
37. F. F. Madrid, and "Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis, and " Cancer Letters, vol. 230, no. 2, pp. 187-198, 2005.
38. M. F. Ullah and M. Aatif, and "The footprints of cancer development: cancer biomarkers, and " Cancer Treatment Reviews, vol. 35, no. 3, pp. 193-200, 2009.
39. H. T. Tan, J. Low, S. G. Lim, and M. C. M. Chung, and "Serum autoantibodies as biomarkers for early cancer detection, and " The FEBS Journal, vol. 276, no. 23, pp. 6880-6904, 2009.
40. C. A. Casiano, M. Mediavilla-Varela, and E. M. Tan, and "Tumorassociated antigen arrays for the serological diagnosis of cancer, and " Molecular and Cellular Proteomics, vol. 5, no. 10, pp. 1745-1759, 2006.
41. P. Boyle, C. J. Chapman, S. Holdenrieder et al. , and "Clinical validation of an autoantibody test for lung cancer, and " Annals of Oncology, vol. 22, no. 2, pp. 383-389, 2011.
42. M. Chatterjee, S. Mohapatra, A. Ionan et al. , and "Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays, and " Cancer Research, vol. 66, no. 2, pp. 1181-1190, 2006.
43. X. Wang, J. Yu, A. Sreekumar et al. , and "Autoantibody signatures in prostate cancer, and "The New England Journal ofMedicine, vol. 353, no. 12, pp. 1224-1235, 2005.
44. D. Lu, E. Kuhn, R. E. Bristow et al. , and "Comparison of candidate serologic markers for type I and type II ovarian cancer, and " Gynecologic Oncology, vol. 122, no. 3, pp. 560-566, 2011.
45. G. Yahalom, D. Weiss, I. Novikov et al. , and "An antibody-based blood test utilizing a panel of biomarkers as a new method for improved breast cancer diagnosis, and " Biomarkers in Cancer. In press.